Get the Stockscreener App
4.58
6.76%
0.29
After Hours:
4.63
0.05
+1.09%
Helus Pharma Inc stock is traded at $4.58, with a volume of 720.19K.
It is up +6.76% in the last 24 hours and down -1.93% over the past month.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
See More
Previous Close:
$4.29
Open:
$4.31
24h Volume:
720.19K
Relative Volume:
0.74
Market Cap:
$228.52M
Revenue:
-
Net Income/Loss:
$-122.31M
P/E Ratio:
-1.0144
EPS:
-4.5151
Net Cash Flow:
$-110.41M
1W Performance:
+18.35%
1M Performance:
-1.93%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$4.2401
$4.63
1-Week Range:
$3.895
$4.63
52-Week Range:
$3.76
$8.5498
Helus Pharma Inc Stock (HELP) Company Profile
Compare HELP vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HELP
Helus Pharma Inc
|
4.58 | 212.05M | 0 | -122.31M | -110.41M | -4.5151 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Helus Pharma Inc Stock (HELP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-13-26 | Initiated | TD Cowen | Buy |
| Feb-02-26 | Initiated | Jefferies | Buy |
| Mar-13-25 | Initiated | Guggenheim | Buy |
| Nov-19-21 | Downgrade | Maxim Group | Buy → Hold |
Helus Pharma Inc Stock (HELP) Latest News
symbol__ Stock Quote Price and Forecast - CNN
Helus Pharma (Nasdaq: CYBN) to speak at H.C. Wainwright Neuro Perspectives - Stock Titan
Helus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Conference - Investing News Network
Helus Pharma medical chief in June 15 neuro conference chat - Stock Titan
Helus Pharma: Trump-Dekret beschleunigt HLP003 - Börse Global
HELP Stock Tanks 22% Despite Strong Phase 2 Results For Anxiety Treatment: Retail Buys The Dip Ignoring Market’s Pessimism - Stocktwits
HELP Stock Crashes On Anxiety Trial Results, But Here’s Why Jefferies Sees Up To 200% Upside - Stocktwits
Helus Pharma reports encouraging Phase 2 results for HLP004 anxiety treatment - MSN
Helus Pharma Showcases Mental Health Pipeline at Jefferies Global Healthcare Conference - TipRanks
Cybin (CYBN) showcases Helus Pharma at Jefferies Global Healthcare Conference - Stock Titan
Helus Pharma to Present at Jefferies Global Healthcare Conference Amid Late-Stage Trials for Depression and Anxiety - citybuzz -
Helus Pharma's CEO to speak at Jefferies Global Healthcare Conference on June 4 - Pluang
Helus Pharma to Participate in the Jefferies Global Healthcare Conference in New York - The Manila Times
Cybin Shares Up Slightly as HELP Backers Focus on Main Trial - Bez Kabli
Helus Pharma (HELP) Stock Analysis Report | Financials & Insights - Benzinga
HELP Should I Buy - Intellectia AI
Helus Pharma Names Michael Cola As CEO For Next Phase Of Growth - Bernama
Helus Pharma CEO Michael Cola steps down; Eric So takes interim CEO role - MSN
Helus Pharma propels therapeutic innovation in mental health and commences trading on Nasdaq - MSN
Helus Pharma Partners With TARA Mind to Boost Phase 3 Depression Trial in Veterans After U.S. Executive Order - TipRanks
Helus Pharma (Nasdaq: HELP) partners with TARA Mind to boost veteran trial access - Stock Titan
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
Jefferies reiterates Helus Pharma stock rating on anxiety data - Investing.com
CORRECTION: Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health - The Manila Times
Cybin Inc. will Change its Name to Helus Pharma - marketscreener.com
Helus turns to TARA Mind to reach veterans for depression trial - Stock Titan
Helus Pharma CEO to Spotlight Mental Health Innovation at 29th Milken Global Conference - TipRanks
Helus Pharma (CYBN) interim CEO to join Milken Global Conference health innovation panel - Stock Titan
Helus Pharma to Participate at the 29th Annual Milken Institute Global Conference - The Manila Times
A Milken health-innovation panel will feature Helus Pharma's interim CEO - Stock Titan
Helus Pharma Partners With TARA Mind to Boost Phase 3 Trial Recruitment for Major Depressive Disorder in Veterans - citybuzz -
Helus Pharma Aligns With U.S. Veteran Mental Health Push in New TARA Mind Partnership - TipRanks
Cybin (CYBN) Helus Pharma joins TARA Mind to boost HLP003 Phase 3 veteran trial - Stock Titan
Helus Pharma partners with TARA Mind for trial recruitment By Investing.com - Investing.com South Africa
Helus Pharma partners with TARA Mind for trial recruitment - Investing.com
Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health - ChartMill
HELP | Cybin Inc. Common Stock Insider Trading - Quiver Quantitative
Does Robert Langer’s Arrival Reframe Confidence in Cybin’s (HELP) Clinical Strategy and Execution Risk? - Yahoo Finance
Helus Pharma Inc Stock (HELP) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.60%
0.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):